University of California Davis, Department of Dermatology, 3301 C St., Suite 1400 Sacramento, CA 95816, USA.
Curr Pharm Des. 2014;20(4):513-28. doi: 10.2174/138161282004140213123852.
Epidemiologic data support the association of psoriasis and psoriatic arthritis with adverse cardiovascular outcomes. Shared pathogenesis in endothelial dysfunction may underlie psoriasis and atherosclerosis. Tumor necrosis factor (TNF) inhibitors may modulate endothelial dysfunction seen in patients with psoriasis and psoriatic arthritis.
To perform a systematic review that investigated endothelial function in psoriasis and psoriatic arthritis and the effect of TNF inhibitors on endothelial function in psoriasis and psoriatic arthritis.
MEDLINE (1980-October 2012), Web of Science, the EULAR abstract database, and the AAD annual meeting abstract archive were searched for cross-sectional or longitudinal studies that 1) examined endothelial function in patients with psoriasis or psoriatic arthritis, or 2) investigated the effect of TNF inhibitor therapy on endothelial function.
Twenty articles and four abstracts with 2261 patients evaluated endothelial function in psoriasis and psoriatic arthritis, which was measured by pulse wave velocity, flow-mediated dilation, nitroglycerine-induced vasodilation, carotid intima-media thickness, peripheral arterial tonometry, or aortic stiffness parameters. The majority of the data suggests that patients with psoriasis and psoriatic arthritis have significantly increased arterial stiffness, impaired endothelial-dependent vasodilation, increased carotid intima-media thickness, and decreased aortic elasticity compared to the general population. Two out of three studies showed that TNF inhibitors improved endothelial function in psoriasis and psoriatic arthritis.
Measurements of endothelial function were not standardized across studies.
The preponderance of literature suggests that endothelial function is significantly impaired in patients with psoriasis and psoriatic arthritis compared to the general population. Preliminary evidence suggests that TNF inhibitors may improve endothelial function in the psoriasis and psoriatic arthritis populations.
流行病学数据支持银屑病和银屑病关节炎与不良心血管结局之间的关联。内皮功能障碍的共同发病机制可能是银屑病和动脉粥样硬化的基础。肿瘤坏死因子(TNF)抑制剂可能调节银屑病和银屑病关节炎患者的内皮功能障碍。
进行系统评价,研究银屑病和银屑病关节炎患者的内皮功能以及 TNF 抑制剂对银屑病和银屑病关节炎患者内皮功能的影响。
检索 MEDLINE(1980 年-2012 年 10 月)、Web of Science、EULAR 摘要数据库和 AAD 年会摘要档案,以寻找评估银屑病或银屑病关节炎患者内皮功能的横断面或纵向研究,或调查 TNF 抑制剂治疗对内皮功能的影响。
20 篇文章和 4 篇摘要共 2261 例患者评估了银屑病和银屑病关节炎患者的内皮功能,通过脉搏波速度、血流介导的扩张、硝酸甘油诱导的血管扩张、颈动脉内膜中层厚度、外周动脉张力测定或主动脉僵硬度参数来测量。大多数数据表明,与普通人群相比,银屑病和银屑病关节炎患者的动脉僵硬度明显增加,内皮依赖性血管扩张受损,颈动脉内膜中层厚度增加,主动脉弹性降低。三项研究中有两项表明 TNF 抑制剂改善了银屑病和银屑病关节炎患者的内皮功能。
研究之间的内皮功能测量未标准化。
大量文献表明,与普通人群相比,银屑病和银屑病关节炎患者的内皮功能明显受损。初步证据表明,TNF 抑制剂可能改善银屑病和银屑病关节炎患者的内皮功能。